StockData

Inventiva vs Entrada Therapeutics

IVA and TRDA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How IVA and TRDA compare

Inventiva grew revenue faster over the last twelve months (−51.3% versus −94.1% for Entrada Therapeutics).

Entrada Therapeutics scores higher on the StockData Score (7 against 1 for Inventiva), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricIVATRDA
Size and price
Market cap–$195M
Share price$3.32$5.00
Change, 1 year−13.1%−43.1%
Change, 5 years−75.2%−82.7%
Beta (5Y)0.640.16
Employees77152
StockData Score
Total score17 (better)
Valuation score01 (better)
Growth score00
Performance score01 (better)
Health score15 (better)
Dividend score00
Valuation
P/S–41.5×
P/B–0.8×
FCF yield–−69.0%
Growth
Revenue growth (TTM)−51.3% (better)−94.1%
Revenue growth, 5Y average64.5%–
Profitability
Operating margin−3146% (better)−3767%
Net margin–−3538%
FCF margin–−2867%
Return on equity–−54.1%
Return on invested capital–−777%
Financial health
Debt / equity–0.00
Interest coverage−0.7×–
Current ratio3.8110.89 (better)
Altman Z-score–−0.97
Piotroski F-score–2
Dividends and buybacks
Shareholder yield–0.00%
Ownership
Held by institutions45.2%75.6%
Held by insiders24.7%14.8%
Insider net buying, 12 months–−$11.5M
Short interest, % of float–8.5%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.